AtriCure Future Growth
Future criteria checks 4/6
AtriCure is forecast to grow earnings and revenue by 60.1% and 11.6% per annum respectively. EPS is expected to grow by 61.1% per annum. Return on equity is forecast to be 2.2% in 3 years.
Key information
60.1%
Earnings growth rate
61.11%
EPS growth rate
| Medical Equipment earnings growth | 16.5% |
| Revenue growth rate | 11.6% |
| Future return on equity | 2.19% |
| Analyst coverage | Good |
| Last updated | 12 Jan 2026 |
Recent future growth updates
AtriCure, Inc. (NASDAQ:ATRC) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Nov 01
AtriCure, Inc. (NASDAQ:ATRC) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 01Recent updates
AtriCure, Inc.'s (NASDAQ:ATRC) 29% Share Price Surge Not Quite Adding Up
Dec 11AtriCure, Inc. (NASDAQ:ATRC) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Nov 01AtriCure, Inc. (NASDAQ:ATRC) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 01AtriCure (NASDAQ:ATRC) Has Debt But No Earnings; Should You Worry?
Jul 08AtriCure: Profits And Operating Leverage Are Needed Here
Jun 26AtriCure, Inc. (NASDAQ:ATRC) Screens Well But There Might Be A Catch
May 01Is AtriCure (NASDAQ:ATRC) A Risky Investment?
Apr 04
cryoSPHERE+ And EnCompass Clamp Launches Will Accelerate Global Adoption
New product launches and international expansion, especially in Europe and China, are key drivers for AtriCure's projected revenue growth and market leadership.Revenues Tell The Story For AtriCure, Inc. (NASDAQ:ATRC) As Its Stock Soars 29%
Jan 22Calculating The Fair Value Of AtriCure, Inc. (NASDAQ:ATRC)
Jan 15Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Dec 24A Piece Of The Puzzle Missing From AtriCure, Inc.'s (NASDAQ:ATRC) 28% Share Price Climb
Nov 06US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results
Nov 01Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?
Oct 31AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 43% Above Its Share Price
Oct 02Further Upside For AtriCure, Inc. (NASDAQ:ATRC) Shares Could Introduce Price Risks After 29% Bounce
Sep 06Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report
Aug 02AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care
Jul 25AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward
Jul 18AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price
May 30Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump
Apr 04Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?
Mar 14Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues
Jan 21Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Nov 29AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price
Sep 27Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?
Aug 02AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion
Jun 15Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?
Apr 14Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)
Mar 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 769 | 29 | N/A | N/A | 3 |
| 12/31/2027 | 677 | 9 | N/A | 84 | 8 |
| 12/31/2026 | 600 | -5 | 41 | 56 | 7 |
| 12/31/2025 | 535 | -18 | 10 | 23 | 1 |
| 9/30/2025 | 518 | -29 | 16 | 43 | N/A |
| 6/30/2025 | 500 | -36 | 8 | 36 | N/A |
| 3/31/2025 | 480 | -38 | -1 | 22 | N/A |
| 12/31/2024 | 465 | -45 | -11 | 12 | N/A |
| 9/30/2024 | 448 | -39 | -1 | 10 | N/A |
| 6/30/2024 | 430 | -40 | -20 | -8 | N/A |
| 3/31/2024 | 415 | -37 | -55 | -12 | N/A |
| 12/31/2023 | 399 | -30 | -38 | 4 | N/A |
| 9/30/2023 | 381 | -25 | -43 | 1 | N/A |
| 6/30/2023 | 366 | -28 | -48 | -3 | N/A |
| 3/31/2023 | 349 | -38 | -18 | -2 | N/A |
| 12/31/2022 | 330 | -46 | -39 | -22 | N/A |
| 9/30/2022 | 316 | -56 | -37 | -22 | N/A |
| 6/30/2022 | 303 | 53 | -32 | -20 | N/A |
| 3/31/2022 | 290 | 52 | -41 | -29 | N/A |
| 12/31/2021 | 274 | 50 | -24 | -14 | N/A |
| 9/30/2021 | 259 | 45 | -18 | -10 | N/A |
| 6/30/2021 | 243 | -57 | -14 | -6 | N/A |
| 3/31/2021 | 213 | -49 | -18 | -13 | N/A |
| 12/31/2020 | 207 | -48 | -25 | -20 | N/A |
| 9/30/2020 | 210 | -46 | -36 | -27 | N/A |
| 6/30/2020 | 212 | -50 | -44 | -34 | N/A |
| 3/31/2020 | 230 | -46 | -31 | -18 | N/A |
| 12/31/2019 | 231 | -35 | -28 | -16 | N/A |
| 9/30/2019 | 222 | -23 | -20 | -11 | N/A |
| 6/30/2019 | 216 | -20 | N/A | -3 | N/A |
| 3/31/2019 | 209 | -17 | N/A | -8 | N/A |
| 12/31/2018 | 202 | -21 | N/A | -4 | N/A |
| 9/30/2018 | 195 | -20 | N/A | -4 | N/A |
| 6/30/2018 | 187 | -20 | N/A | -9 | N/A |
| 3/31/2018 | 180 | -27 | N/A | -9 | N/A |
| 12/31/2017 | 175 | -27 | N/A | -9 | N/A |
| 9/30/2017 | 170 | -33 | N/A | -10 | N/A |
| 6/30/2017 | 166 | -32 | N/A | -9 | N/A |
| 3/31/2017 | 160 | -34 | N/A | -14 | N/A |
| 12/31/2016 | 155 | -33 | N/A | -15 | N/A |
| 9/30/2016 | 150 | -36 | N/A | -20 | N/A |
| 6/30/2016 | 143 | -35 | N/A | -18 | N/A |
| 3/31/2016 | 135 | -32 | N/A | -10 | N/A |
| 12/31/2015 | 129 | -27 | N/A | -8 | N/A |
| 9/30/2015 | 123 | -22 | N/A | -6 | N/A |
| 6/30/2015 | 118 | -16 | N/A | -10 | N/A |
| 3/31/2015 | 112 | -14 | N/A | -16 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ATRC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.3%).
Earnings vs Market: ATRC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ATRC is expected to become profitable in the next 3 years.
Revenue vs Market: ATRC's revenue (11.6% per year) is forecast to grow faster than the US market (10.1% per year).
High Growth Revenue: ATRC's revenue (11.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ATRC's Return on Equity is forecast to be low in 3 years time (2.2%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/02 18:16 |
| End of Day Share Price | 2026/01/30 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AtriCure, Inc. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charley Jones | Barrington Research Associates, Inc. |
| Marie Thibault | BTIG |
| Michael Gorman | BTIG |